Group A
Preclinical
Group A is one of 12 therapeutic programs targeting Crohn Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
15 competitors in Crohn Disease
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonApproved
Stelara
Johnson & JohnsonPhase 3
Skyrizi
AbbViePhase 3
JNJ-78934804
Johnson & JohnsonPhase 3
Xifaxan
SSalix
Phase 2
LY4395089
Eli LillyPhase 2
Mirikizumab - Intravenous (IV)
Eli LillyPhase 2
Mirikizumab - Subcutaneous (SC)
Eli LillyPhase 2
Icotyde
Johnson & JohnsonPreclinical
MTP-101C
UUniversity of Minnesota
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Group A. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- ZZhu Weiming